Vet Pathol Download to Citation Manager
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Opriessnig, T.
Right arrow Articles by Halbur, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Opriessnig, T.
Right arrow Articles by Halbur, P. G.
Vet Pathol 40:521-529 (2003)
© 2003 American College of Veterinary Pathologists

Effect of Vaccination with Selective Bacterins on Conventional Pigs Infected with Type 2 Porcine Circovirus

T. Opriessnig, S. Yu, J. M. Gallup, R. B. Evans, M. Fenaux, F. Pallares, E. L. Thacker, C. W. Brockus, M. R. Ackermann, P. Thomas, X. J. Meng and P. G. Halbur

Departments of Veterinary Diagnostic and Production Animal Medicine (TO, PGH, RBE, FP), Veterinary Microbiology and Preventive Medicine (SY, ELT), and Veterinary Pathology (JMG, CWB, MRA), College of Veterinary Medicine, Iowa State University, Ames, IA; Department of Biomedical Sciences and Pathobiology, Center for Molecular Medicine and Infectious Diseases, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA (MF, XJM); and Departamento de Anatomía y Anatomía Patológica Comparada, Facultad de Veterinaria, Universidad de Murcia, Murcia, Spain (FP)


    Abstract
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
The objective of this study was to determine whether vaccination with bacterins commonly used in the USA, when administered at a time typical of US protocol, enhances porcine circovirus type 2 (PCV2) replication and the incidence and severity of clinical signs and lesions characteristic of postweaning multisystemic wasting syndrome (PMWS) in conventional pigs. Sixty-one pigs free of PCV2 were randomly assigned to four groups. Groups 1 (n = 15) and 2 (n = 15) pigs served as sham-inoculated negative controls. Groups 3 (n = 14) and 4 (n = 17) pigs were inoculated intralymphoid with PCV2 field isolate ISU-40895. Pigs in groups 2 and 4 were vaccinated with Actinobacillus pleuropneumoniae (APP) and Mycoplasma hyopneumoniae (M. hyopneumoniae) bacterins 21 days before and again 1 day before inoculation with PCV2. Mild transient respiratory disease and diarrhea were observed from 13 to 34 days postinoculation (DPI) in pigs in groups 3 and 4. Half the pigs from each group were necropsied at 22 and 34 DPI, respectively. Moderately enlarged, tan-colored lymph nodes were observed in the majority of pigs in groups 3 and 4. There was a significantly (P < 0.05) longer length of viremia (2.14 ± 0.26 versus 4.44 ± 0.23 weeks), a higher copy number of the PCV2 genome in serum, a wider range of tissue distribution of PCV2 antigen, and an increased severity of lymphoid depletion in pigs vaccinated with commercial APP and M. hyopneumoniae vaccines and inoculated with PCV2 compared with PCV2-inoculated unvaccinated pigs. Swine producers and veterinarians may need to consider changes in vaccination protocols in herds with recurrent PCV2-associated PMWS.


Key words: Immune stimulation; porcine circovirus 2; postweaning multisystemic wasting syndrome; vaccination.

Two types of porcine circovirus (PCV), referred to as type 1 PCV (PCV1) and type 2 PCV (PCV2), have been characterized in pigs.5,24 PCV is a very small, nonenveloped, single-stranded DNA virus with a circular genome33 and belongs to the Circoviridae family.23 PCV1 was first recognized in 1974 as a cell culture contaminant.35 Experimental PCV1 infections have demonstrated no effect in pigs; thus, PCV1 is considered to be nonpathogenic.3,34 PCV2 was first recognized to be associated with postweaning multisystemic wasting syndrome (PMWS) in 1996.12 PMWS is characterized clinically by enlargement of the lymph nodes, chronic pneumonia, progressive weight loss, and less commonly by icterus, pallor, or diarrhea. Characteristic microscopic lesions include lymphoid depletion and histiocytic replacement of follicles in lymphoid tissues. Mild-to-severe granulomatous inflammation in lymphoid and other tissues also is commonly observed. Macrophages in affected lymphoid tissues may contain basophilic inclusion bodies.1,31

Serologic studies demonstrate that PCV2 is ubiquitous in the swine population, and essentially all herds are infected.22,36 In contrast, PMWS is manifested in a relatively low percentage of pigs in PCV2-infected herds.1 It has been demonstrated that other coinfections such as porcine reproductive and respiratory disease virus (PRRSV)4,14,30 or porcine parvovirus (PPV)2,16,18 may potentiate the development of PMWS in PCV2-infected pigs.

Recent studies have demonstrated that immune stimulation may trigger progression of PCV2 infection to disease and lesions characteristic of PMWS. Krakowka et al.17 reproduced PMWS in gnotobiotic pigs stimulated with keyhole limpet hemocyanin in Freund's incomplete adjuvant (KLH–ICFA) and infected with PCV2. Allan et al.6 observed PMWS in 21% of PCV2-infected and vaccinated (Mycoplasma hyopneumoniae [M. hyopneumoniae] at 13 and 31 days of age, and Actinobacillus pleuropneumoniae [APP] at 47 days of age) colostrum-fed pigs. In contrast, another recent study using conventional pigs failed to demonstrate an immune-stimulation–dependent difference in pigs inoculated with PCV2 and stimulated with KLH–ICFA.20 These experimental models suggest that immune stimulation may in some cases increase the incidence and severity of PMWS in PCV2-infected pigs.

Field trials further supported this hypothesis. Vaccination of piglets with a M. hyopneumoniae bacterin at 1 and 4 weeks of age resulted in a significant increase in losses associated with of PMWS in the vaccinated pigs in two of five batches.7 Kyriakis et al.19 vaccinated a portion of the pigs in a herd experiencing a PMWS outbreak with a M. hyopneumoniae vaccine and observed PMWS in 43% of the vaccinated pigs compared with 11% of the nonvaccinated pigs.

The objective of this study was to determine whether vaccination with bacterins (APP and M. hyopneumoniae) commonly used in the USA at a time typically administered in USA enhances the incidence and severity of PCV2-associated PMWS lesions in conventional pigs.


    Materials and Methods
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Animal source

Sixty-one pigs were weaned at 12–14 days of age and brought to the livestock infectious disease isolation facility at Iowa State University. All pigs were tested by enzyme-linked immunosorbent assay (ELISA) and confirmed to be negative for antibodies to PCV2.28 The pigs were assigned randomly to rooms and pens and were housed in two rooms, with four pens in each room.

Experimental design

The experimental design is shown in Table 1. Pigs were 7–10 weeks of age when inoculated with PCV2. For the sham-inoculation, the pigs in groups 1 and 2 received a similar volume of a 0.9% sodium chloride solution (Lot 65-181-DK; Abbot Laboratories, North Chicago, Illinois). Half the pigs were necropsied at 22 days postinoculation (DPI) and the remaining pigs at 34 DPI.


View this table:
[in this window]
[in a new window]
 
Table 1. Experimental design.

 
Vaccines

A Mycoplasma hyopneumoniae (M. hyopneumoniae) bacterin (M+PAC®, Schering-Plough Animal Health, Omaha, Nebraska; Lot EX-0061-1108-01) and an APP bacterin (Serotypes 1, 5, and 7, PNEU PAC®, Schering-Plough Animal Health, Lot NDC-0061-0260-01) were used for immune stimulation. The APP vaccine was adjuvanted with emulsified paraffin and the M. hyopneumoniae bacterin contained Emunade®, a combination of aluminum hydroxide with oil-in-water dual-action adjuvant. The first dose of each vaccine was given 21 days before and the second dose was given 1 day before PCV2 inoculation. Each pig was vaccinated intramuscularly in the right neck with 2 ml of the APP and in the left neck with 1 ml of the M. hyopneumoniae bacterins according to the manufacturer's directions.

Virus inoculum

The PCV2 isolate used in this study, field isolate ISU-40895, was originally obtained from a pig with PMWS in a herd in western Iowa with mild-to-moderate losses associated with PMWS.9 The virus preparation was done on PK-15 cells free of PCV1 and PCV2, as described previously.10 Briefly, PK-15 cells were cultivated in T-25 culture flasks and transfected with the PCV2-infectious DNA clone.10 The transfected cells were harvested at 3 days posttransfection by freezing and thawing at -80 C three times. The infectious titer of the inoculum was determined by immunofluorescence assay as described previously.10 The virus inoculum was stored at -80 C until use. Each pig in groups 3 and 4 received 8 ml of isolate ISU-40895 with a titer of about 103.5 tissue culture infective dose50 intralymphoid. One half of the inoculum was injected in the right and the other half in the left superficial inguinal lymph node.10

Clinical evaluation

The pigs were evaluated daily for clinical signs, including respiratory disease (score ranging from 0 [normal breathing] to 6 [severe dyspnea and abdominal breathing]).11 Nasal discharges and coughing were recorded by observers along with other changes such as lethargy. Rectal temperatures were recorded daily. The pigs were weighed at 20 and 3 days before inoculation and at 22 and 34 DPI.

Serology

Serum samples were taken before inoculation and at 7, 13, 21, 28, and 33 DPI. A PCV2-ELISA based on the recombinant open reading frame 2–capsid protein of PCV2 was performed on serum samples of all pigs as described previously.28 Samples with a sample-to-positive (S : P) ratio >= 0.2 were considered to be positive for antibodies to PCV2.

In addition, serum of all pigs was tested for the presence of specific antibodies to porcine parvovirus by hemagglutination inhibition (HI),25 and for the presence of PRRSV-specific antibodies by PRRSV ELISA (IDEXX Laboratories, Inc. Westbrook, MA) on 33 DPI.

Gross pathology and histopathology

At necropsy, macroscopic lung lesions (0–100% of the lung affected) and size of lymph nodes (score ranging from 0 [normal] to 3 [three times the normal size]) were determined. Bronchoalveolar lavage (BAL) for bacterial and virologic examinations was collected as described previously.26

Tissue samples from lymph nodes (superficial inguinal, mediastinal, tracheobronchial, and mesenteric), lung, tonsil, thymus, ileum, kidney, colon, skin, spleen, liver, stomach, bone marrow, and ribs were collected during necropsy and fixed in 10% formalin and routinely processed for histologic examination. Microscopic lesions were evaluated blindly by a veterinary pathologist.

Immunohistochemistry

Immunohistochemistry (IHC) for detection of PCV2-specific antigen was performed on sections of paraffin blocks of selected tissue samples (lymph nodes, including superficial inguinal, mediastinal, tracheobronchial, and mesenteric, tonsil, and spleen) using a rabbit polyclonal antiserum as described previously.32 The amount and distribution of PCV2 antigen was compared by evaluation of IHC signals of each tissue section ranging from 0 (= no signal) to 3 (= strong positive signals) in a blinded fashion. The mean group score was determined for each lymphoid tissue and compared between groups.

Polymerase chain reaction

To confirm the presence of PCV2 infection and for the assessment of the length of PCV2 viremia, polymerase chain reaction (PCR) was performed on serum samples collected at different DPIs. Deoxyribonucleic acid (DNA) from weekly serum samples was extracted using a commercial DNA isolation kit (QIAamp® DNA Blood Mini Kit, Qiagen, Valencia, California). PCR was performed as described previously.9 As a positive control for DNA extraction and PCR, PCV2 isolate ISU-98-15237 was used.

Quantitative PCR

Sequence-specific oligonucleotide primers and a fluorescent probe for detection and relative quantification of PCV2 genomic DNA were designed using computer software (ABI Prism Primer Express, Version 1.5, PE Applied Biosystems, Foster City, California) according to the manufacturer's suggestions and were engineered to be within a highly conserved region of the viral genome (Table 2). The PCR reaction consisted of 50 µl PCR mixtures that contained 25 µl of the commercially available master mix (TaqMan Universal PCR Master Mix, PE Applied Biosystems), 5 µl DNA extract from each pig serum, forward and reverse primers, and detection probe with concentrations of 400, 400, and 200 nM, respectively. All reactions were carried out in triplicate. In addition, each reaction included three replicates for each of the five progressive 1 : 10 dilutions of a known copy number of PCV2 genomic DNA excised from a purified PCV2 DNA clone that served to generate a standard curve. Each plate was run in the sequence detection system (GeneAmp 5700 Sequence Detection System, Applied Biosystems) under company-specified conditions that were optimal (2 minutes at 50 C, 10 minutes at 95 C, followed by 45 cycles of 15 seconds at 95 C and 1 minute at 60 C) for the Taq Master Mix used.


View this table:
[in this window]
[in a new window]
 
Table 2. Sequences of the primer and TaqMan fluorescent probe used in fluorogenic realtime PCR for absolute quantification of PCV2 genomic DNA in serum samples. 6FAM = fluorescent reporter dye; TAMRA = fluorescent quencher dye.

 
Bone marrow analysis

On both necropsy days, 22 and 34 DPI, bone marrow specimens were collected from the distal femur and were placed immediately into an ethylenediaminetetraacetic acid tube containing 0.5 ml sterile normal saline and 0.1 ml albumin and mixed to disperse cells. Two to three slides per animal were then prepared by cytospin preparation, and three 500 cell-count differentials were performed on each animal.

Statistical analyses

Chi-square test was used to analyze the clinical scores. Daily rectal temperatures were analyzed with multiple analysis of covariance (MANCOVA), which accounts for the repeated measures on each pig and for baseline temperature. For the pigs that were necropsied at 22 DPI, all the data were analyzed from 0 to 21 DPI. For the remaining pigs, the data were analyzed from 0 to 31 DPI. If the time-by-group interaction was not significant, then the group effect was assessed. Otherwise, the data were analyzed cross-sectionally to determine at which time points the group means are different. MANCOVA also was chosen for analyzing the weight data, which accounted for the repeated measurements of each pig and for baseline weight at 20 days before inoculation. Analysis of ELISA results was done by using cross-sectional analysis (analysis of variance [ANOVA]), and differences between groups were evaluated with Tukey's test. Nonrepeated measures of necropsy and histopathology data were assessed using analysis of covariance (ANCOVA) or nonparametric ANOVA. If a nonparametric ANCOVA test was significant (P < 0.05), then Wilcoxon tests (with the Bonferroni correction) were used to assess the differences of pairs of groups. Fisher's exact test was used to compare the incidence between groups.

Statistical analysis for real-time PCR was performed using the means of three replicate wells for each sample as compared with a standard curve generated with a purified known genome copy number of PCV2 genomic DNA ranging from 103 to 107 genomic copies per PCR plate well. Serial dilutions (1 : 10) between each standard resulted in a 5-point standard curve with a correlation of >0.992. The threshold cycle (threshold cycle CT, is the cycle number at which a statistically significant increase in amplification above the threshold line [0.1 in all cases] is first detected) of triplicate unknowns were compared with CTs of triplicate standards on a standard curve to determine the absolute number of viral genomes per milliliter of pig serum.


    Results
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Clinical signs

Pigs in the sham-inoculated control groups 1 and 2 showed no clinical signs of disease throughout the study. Pigs in PCV2-infected groups 3 and 4 exhibited intermittent diarrhea and mild respiratory disease from 13 DPI until the end of the study at 34 DPI. The respiratory disease was characterized by sneezing, clear nasal discharge, and occasional coughing. Statistical analysis of the clinical scores (chi-square test) revealed that the clinical respiratory disease scores in pigs of groups 3 and 4 were statistically more severe than those of groups 1 and 2 pigs (P < 0.0001). There was no difference in clinical scores between pigs of groups 3 and 4 (P = 0.6). Statistical analysis of the daily rectal temperatures (0 to 33 DPI) showed neither a significant group-by-time interaction (P = 0.14) nor a significant group effect (P = 0.08). Statistical analysis of the weight data showed no statistically significant difference in time-by-group effect (P = 0.8) or group effect (P = 0.6). At 34 DPI, the average weights appeared to differ (49.1 kg [± 5.4] in group 1 pigs, 47.9 kg [± 4.2] in group 2 pigs, 48.6 kg [± 7.5] in group 3 pigs, and 45.6 kg [± 4.7] in group 4 pigs], but there was substantial variability within each group. The average daily weight gain was 0.70 kg (± 0.05) for group 1 pigs, 0.67 kg (± 0.05) for group 2 pigs, 0.70 kg (± 0.08) for group 3 pigs, and 0.63 kg (± 0.09) for group 4 pigs.

Gross lesions

In sham-inoculated control groups 1 and 2, only 4 of the 30 pigs had visible gross lesions. The four pigs with lesions were necropsied at 34 DPI and had lymph node enlargement of approximately two times the normal size. There were significantly more pigs in groups 3 and 4 (P < 0.05) with enlarged lymph nodes (Table 3) compared with groups 1 and 2. In group 3, 12 of 14 pigs had enlargement of all lymph nodes from two to three times the normal size. In group 4, 15 of 17 pigs had lymph node enlargement of two to three times the normal size. The macroscopic evaluation of the lymph node sizes showed no statistical difference between groups 3 and 4 at the first (P = 0.33) or second (P = 0.3) necropsy.


View this table:
[in this window]
[in a new window]
 
Table 3. Gross and microscopic lesions in control and PCV2-inoculated 7- to 10-week-old conventional pigs at 22 and 34 DPI.*.

 
Microscopic lesions and IHC

There were no microscopic lesions in the lymph nodes of pigs in groups 1 and 2. In groups 3 and 4, microscopic lesions characterized by lymphoid depletion of follicles and granulomatous lymphadenitis were observed in nearly all pigs: 12 of 14 in group 3 pigs, and 16 of 17 in group 4 pigs. At 34 DPI, there was a significant difference (P = 0.02) in severity of lymphoid depletion between groups 3 (mean = 0.86) and 4 (mean = 1.56). Mild to moderate lymphoplasmacytic interstitial nephritis was observed in 1 of 15 group 1 pigs, in 4 of 14 group 3 pigs, and in 5 of 17 group 4 pigs. Mild lymphohistiocytic hepatitis was observed in 7 of 14 pigs in group 3 and in 11 of 17 pigs in group 4. Mild to moderate lymphohistiocytic enteritis was observed in 6 of 14 pigs in group 3 and in 7 of 17 pigs in group 4 (Table 3).

PCV2 antigen was detected by IHC in a variety of tissues (lymph nodes, spleen, and tonsil) in groups 3 and 4. At 22 DPI, PCV2 antigen was detected in all pigs examined. There was no difference between the amount and distribution of PCV2 antigen between groups 3 and 4 at 22 DPI. At 34 DPI, PCV2 antigen was only detected in the lymph nodes in 4 of 7 group 3 pigs. In contrast, at DPI 34, PCV2 antigen was still detectable in the lymph nodes of all group 4 pigs (9 of 9), and the amount of PCV2 antigen in the lymph nodes was significantly (P < 0.05) higher in group 4 than in group 3 pigs at 34 DPI (Table 4).


View this table:
[in this window]
[in a new window]
 
Table 4. Comparison of estimated amount of PCV2 antigen (ranging from 0 = not detectable to 3 = strong signal) in lymphoid tissues between groups 3 (PCV2 infected) and 4 pigs (PCV2 infected and vaccinated).

 
Antibody response

Pigs in groups 1 and 2 remained seronegative for PCV2 antibody throughout the study. Pigs in groups 3 and 4 seroconverted to PCV2 between 21 and 28 DPI. Cross-sectional analysis (using ANOVA) indicated that there were statistically different group means (P < 0.0001) at 21, 28, and 33 DPI. A Tukey's test showed that for each day neither were groups 1 and 2 statistically different from each other nor were groups 3 and 4 different from each other. All serum samples tested were negative for presence of PRRSV- and PPV-specific antibodies at 33 DPI.

PCV2 viremia

In groups 1 and 2, all serum samples collected at different DPIs were negative for PCV2 DNA by PCR. Viremia in groups 3 and 4 pigs was detected as early as 7 DPI in 24 of 31 pigs. All pigs in groups 3 and 4 were viremic at 13 DPI. By 21 DPI, 11 of 14 pigs in group 3 and 16 of 17 pigs in group 4 remained positive with PCV2 DNA. By 28 DPI, 1 of 7 pigs in group 3 was positive for PCV2 DNA in sera, whereas 7 of 9 pigs in group 4 were positive. At 33 DPI, the day before necropsy, 7 of 9 pigs in group 4 were still positive for PCV2 DNA, whereas none of the pigs (0 of 7) in group 3 were positive. The PCR data were analyzed using nonparametric ANOVA as an omnibus test and Wilcoxon pairwise post hoc tests. The overall test was significant (P < 0.001), and post hoc tests indicated that groups 3 and 4 were different (P = 0.03) from each other and from groups 1 and 2 (P < 0.0001). To determine the length of viremia, only the animals that were alive at the end of the study were analyzed. Pigs necropsied at 22 DPI were not included. The mean viremia length observed in group 3 pigs (n = 7) was 2.14 (±0.26) weeks, compared with 4.44 (±0.23) weeks in group 4 pigs (n = 9). The length of viremia in group 4 pigs was determined by the end of the study at 34 DPI. At this time point, 7 of 9 group 4 pigs were still viremic, whereas none of the nonvaccinated group 3 pigs were viremic. The difference in viremia length between groups 3 and 4 was highly significant (P = 0.0003).

PCV2 genome titer in sera

Analysis of the amount of PCV2 genomic DNA per milliliter of serum revealed major differences between groups 3 and 4 pigs. The mean copy number of PCV2 genomic DNA measured in nonvaccinated group 3 pigs was 1.3 x 105 genomic copies per milliliter serum at 7 DPI. On the following testing dates (13–33 DPI), the PCV2 genomic titer decreased in all pigs to 6.1 x 103 PCV2-copies per milliliter serum at 33 DPI. In contrast, the mean copy number of PCV2 genome in sera measured in vaccinated group 4 pigs was 2.7 x 107 copies per milliliter serum at 7 DPI. Furthermore, in the majority of group 4 pigs (7 of 9), the PCV2 genomic titer remained at a relatively high level (mean copy number per milliliter serum between 2.3 x 106 at 14 DPI and 1.7 x 106 at 33 DPI) compared with nonvaccinated group 3 pigs during the entire experiment. Instead of decreasing, PCV2 genomic titer continued to increase over time in some pigs. Figure 1 illustrates the comparison of group mean PCV2 genome titer. Differences in the amount of PCV2 genome copy number between both groups were significant (P < 0.05) on 13, 21, 28, and 32 DPI.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1. PCV2 genomic titers in sera measured by quantitative real-time PCR. The values are the mean group results for group 3 (nonvaccinated, n = 7) and group 4 (vaccinated, n = 9) pigs. Pigs that were necropsied at 22 DPI are not included. Error bars represent standard errors.

 
Bacteriology

There was no growth on cultures of the BAL-fluid in any of the pigs from groups 1 to 4.

Bone marrow analysis

All the variables were analyzed using nonparametric ANOVA. There were no significant differences between the groups. Erythroid and myeloid cell series were present and followed a normal maturation sequence. M : E ratios were within reference intervals for this species. Megakaryocytes were observed in all specimens. One interesting feature was the presence of many eosinophils on marrow cytospin preparations; eosinophils are rarely observed on peripheral complete blood count differentials.


    Discussion
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
The objective of this study was to determine whether M. hyopneumoniae and APP vaccination enhanced the incidence and severity of PMWS disease and lesions associated with PCV2 infection of conventional pigs. At least three European studies, one using an experimental model6 and two recent field studies,7,19 provide evidence that vaccine-induced immune stimulation enhances PCV2 replication and increases the incidence of clinical PMWS. The results of these European studies are not ideally suited for application to the US field situation, where M. hyopneumoniae vaccines are typically used on older pigs. In the USA, PCV2-associated PMWS is most commonly observed in pigs aged 8–20 weeks,13,15 whereas in Europe it is observed in pigs aged 3–10 weeks.1 M. hyopneumoniae vaccination in the USA is typically done in nursery-age pigs from 3 to 10 weeks, whereas in Europe it is more commonly done on suckling pigs or on pigs in the early nursery phase at 1–4 weeks of age. We attempted to mimic the immune stimulation approach of the European studies by vaccinating pigs with M. hyopneumoniae and APP; however, we vaccinated at 5 and 7 weeks of age using segregated early-weaned (12–14 days) pigs, consistent with current US production systems.

Diagnostic criteria of PMWS include clinical evidence of wasting, histologic evidence of lymphoid depletion or granulomatous lymphadenitis, and the presence of PCV2 antigen or nucleic acids associated with the characteristic lymphoid lesions.31 PCV2-associated microscopic lesions consistent with PMWS were observed in both PCV2-inoculated groups in this study; however, we failed to reproduce clinical manifestation of PMWS. This might be due to removal of other key stressors not present in the clean experimental environment. Unlike most field situations, our pigs had no known concurrent viral or bacterial coinfections, which have been shown to increase the incidence and severity of PMWS in PCV2-infected pigs.2,4,14,16,18,30 The PCV2 inoculum was a pure and homogeneous infectious stock derived from an infectious DNA clone of PCV2 isolate ISU-40895, which was originally isolated from a pig with PMWS.9,10 Therefore, the disease and lesions reproduced in this study perhaps are more definitive than those using tissue homogenate or cell culture–propagated PCV2 inoculum, which might contain other common swine agents. The differences in environment and coinfection may at least partly explain the differences in results of different experiment models and differences in severity of PCV2-associated disease from farm to farm.

Pigs in the vaccinated and nonvaccinated PCV2-infected groups developed microscopic lesions consistent with PMWS. This observation in the nonvaccinated group 3 is in contrast to many PCV2 experimental models, where no or mild microscopic lesions typical of PCV2-associated disease were observed.4,17,18,29,30 There are only a few reports to date which describe reproduction of severe microscopic lesions characteristic of PMWS with singular PCV2 inoculation.8,20,21 Differences in experimental results could be explained by PCV2 strain variation, individual pig susceptibility differences, differences in age of inoculation, or type of animal housing. Typically, more severe lesions were observed in young gnotobiotic pigs,17,18 cesarean-derived-colostrum–deprived pigs,8,14 and colostrum-deprived pigs,2,4,16 compared with "conventional pigs."30 The definition of conventional pigs also may vary. In our case, these are genetics typical of the current US swine industry; pigs free of several major pathogens (PRRSV, SIV, PCV2, APP, M. hyopneumoniae) and early weaned to a distant site where they are reared in all-in-all-out fashion.

The length of PCV2 viremia in the unvaccinated group 3 pigs (2.14 ± 0.26 weeks) was consistent with observations of other research groups.10,29 PCV2-associated lymphoid lesions peaked around 22 DPI and were minimal or absent in the nonvaccinated pigs at the end of the study at 34 DPI. In contrast, pigs in the vaccinated group 4 had significantly longer length of PCV2 viremia (4.44 ± 0.23 weeks) and a longer duration of PCV2 antigen detection in various lymphoid tissues. Quantitative PCR results further confirmed the significantly (P < 0.05) higher amount of PCV2 genome titers in sera of vaccinated pigs compared with that of nonvaccinated pigs. However, this did not influence the clinical appearance of the pigs in this study. Only mild respiratory disease and mild diarrhea were observed. Nevertheless, the increased length of viremia may increase the window of opportunity for coinfecting agents or other cofactors to trigger progression of PCV2 infection to PMWS.

Most modern pig production systems use some type of vaccine, particularly in 2- to 12-week–old pigs. It has been speculated that both the use of vaccines and the type of vaccine may play an important role in the manifestation of clinical PMWS.6,19 In addition to the type of vaccine used, the timing of vaccination also may be important. This difference might be reflected in this current study, where none of the pigs vaccinated between 5 and 10 weeks of age developed clinical PMWS, whereas in a previous study6 with an earlier onset of vaccination (2 weeks of age), PMWS was developed in 21% of the pigs. Early vaccination, high virus prevalence in the environment, and low maternal antibody status may lead to increased incidence and severity of PMWS typical of what is occurring in the UK, where the postweaning mortalities have increased by 5–40% in many affected herds.27

PMWS is a disease complex influenced by many factors. One of these factors may be commonly used vaccines. However, on a herd basis, the risk of elimination of effective vaccines may be greater than the risk of inducing PMWS in a low percentage of the population. Further work is warranted to determine whether there is an optimal time for vaccination and if certain types of adjuvants or antigens play a role in vaccine-induced enhancement of PMWS. Swine producers may need to consider changing vaccine products or regimens to minimize PCV2 replication and PCV2-associated diseases in affected herds.


    Acknowledgments
 
We thank the Iowa State University Livestock Infectious Disease Isolation Facility staff for animal care. This study was funded in part by Pork Check of Dollars from the National Pork Board and a grant from the Iowa Livestock Health Advisory Council.


    References
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Allan GM, Ellis JA: Porcine circoviruses: a review. J Vet Diagn Invest 12:3-14, 2000[Abstract/Free Full Text]
  2. Allan GM, Kennedy S, McNeilly F, Foster JC, Ellis JA, Krakowka SJ, Meehan BM, Adair BM: Experimental reproduction of severe wasting disease by co-infection of pigs with porcine circovirus and porcine parvovirus. J Comp Pathol 121:1-11, 1999[CrossRef][ISI][Medline]
  3. Allan GM, McNeilly F, Cassidy JP, Reilly GAC, Adair B, Ellis WA, McNulty MS: Pathogenesis of porcine circovirus; experimental infections of colostrum deprived piglets and examination of pig foetal material. Vet Microbiol 44:49-64, 1995[CrossRef][ISI][Medline]
  4. Allan GM, McNeilly F, Ellis J, Krakowka S, Meehan B, McNair I, Walker I, Kennedy S: Experimental infection of colostrum deprived piglets with porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) potentiates PCV2 replication. Arch Virol 145:2421-2429, 2000[CrossRef][ISI][Medline]
  5. Allan GM, McNeilly F, Kennedy S, Daft B, Clark EG, Ellis JA, Haines DM, Meehan BM, Adair BM: Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe. J Vet Diagn Invest 10:3-10, 1998[Abstract/Free Full Text]
  6. Allan GM, McNeilly F, Kennedy S, Meehan B, Ellis J, Krakowka S: Immunostimulation, PCV-2 and PMWS. Vet Rec 147:170-171, 2000[ISI][Medline]
  7. Allan GM, McNeilly F, McNair I, O'Connor M, Meehan B, Gilpin D, Ellis J, Townsend H, Lasagna C, Boriosi G, Krakowka S: Neonatal vaccination for Mycoplasma hyopneumoniae and post-weaning multisystemic wasting syndrome: a field trial. Pig J 48:34-41, 2001
  8. Bolin SR, Stoffregen WC, Nayar GPS, Hamel AL: Postweaning multisystemic wasting syndrome induced after experimental inoculation of cesarean-derived, colostrums-deprived piglets with type 2 porcine circovirus. J Vet Diagn Invest 13:185-194, 2001[Abstract/Free Full Text]
  9. Fenaux M, Halbur PG, Gill M, Toth TE, Meng XJ: Genetic characterization of type 2 porcine circovirus (PCV-2) from pigs with postweaning multisystemic wasting syndrome in different geographic regions of North America and development of a differential PCR-restriction fragment length polymorphism assay to detect and differentiate between infections with PCV-1 and PCV-2. J Clin Microbiol 38:2494-2503, 2000[Abstract/Free Full Text]
  10. Fenaux M, Halbur PG, Haqshenas G, Royer R, Thomas P, Nawagitgul P, Gill M, Toth TE, Meng XJ: Cloned genomic DNA of type 2 porcine circovirus is infectious when injected directly into the liver and lymph nodes of pigs: characterization of clinical disease, virus distribution, and pathologic lesions. J Virol 76:541-551, 2002[Abstract/Free Full Text]
  11. Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng XJ, Lum MA, Andrews JJ, Rathje JA: Comparison of the pathogenictiy of two U. S. porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet Pathol 32:648-660, 1995[Abstract]
  12. Harding JCS, Clark EG: Recognizing and diagnosing postweaning multisystemic wasting syndrome (PMWS). Swine Health Prod 5:201-203, 1997
  13. Harms PA, Halbur PG, Sorden SD: Three cases of porcine respiratory disease complex associated with porcine circovirus type 2 infection. J Swine Health Prod 10:27-30, 2002
  14. Harms PA, Sorden SD, Halbur PG, Bolin SR, Lager KM, Morozov I, Paul PS: Experimental reproduction of severe disease in CD/CD pigs concurrently infected with type 2 porcine circovirus and porcine reproductive and respiratory syndrome virus. Vet Pathol 38:528-539, 2001[Abstract/Free Full Text]
  15. Harms PA, Sorden SD, Halbur PG, Nawagitgul P, Lager K, Bolin S, Paul PS: Role of maternal immunity to PCV2 and PRRSV co-infection in the pathogenesis of PMWS. Proc Am Assoc Swine Vet 33:307-311, 2002
  16. Kennedy S, Moffett D, McNeilly F, Meehan B, Ellis J, Krakowka S, Allan GM: Reproduction of lesions of postweaning multisystemic wasting syndrome by infection of conventional pigs with porcine circovirus type 2 alone and in combination with porcine parvovirus. J Comp Pathol 122:9-24, 2000[CrossRef][ISI][Medline]
  17. Krakowka S, Ellis JA, McNeilly F, Ringler S, Rings DM, Allan G: Activation of the immune system is the pivotal event in the production of wasting disease in pigs infected with porcine circovirus-2 (PCV2). Vet Pathol 38:31-42, 2001[Abstract/Free Full Text]
  18. Krakowka S, Ellis JA, Meehan B, Kennedy S, McNeilly F, Allan G: Viral wasting syndrome of swine: experimental reproduction of postweaning multisystemic wasting syndrome in gnotobiotic swine by coinfection with porcine circovirus 2 and porcine parvovirus. Vet Pathol 37:254-263, 2000[Abstract/Free Full Text]
  19. Kyriakis SC, Saoulidis K, Lekkas S, Miliotis CC, Papoutsis PA, Kennedy S: The effects of immuno-modulation on the clinical and pathological expression of postweaning multisystemic wasting syndrome. J Comp Pathol 126:38-46, 2002[CrossRef][ISI][Medline]
  20. Lakekjær-Mikkelsen A, Nielsen J, Stadejek T, Storgaard T, Krakowka S, Ellis J, McNeilly F, Allan G, Bøtner A: Reproduction of postweaning multisystemic wasting syndrome (PMWS) in immunostimulated and non-immunostimulated 3-week-old piglets experimentally infected with porcine circovirus type 2 (PCV2). Vet Microbiol 22:89-97, 2002
  21. Magar R, Larochelle R, Thibault S, Lamontagne L: Experimental transmission of porcine circovirus type 2 (PCV2) in weaned pigs: a sequential study. J Comp Pathol 123:258-269, 2000[CrossRef][ISI][Medline]
  22. Magar R, Muller P, Larochelle R: Retrospective serological survey of antibodies to porcine circovirus type 1 and type 2. Can J Vet Res 64:184-186, 2000[ISI][Medline]
  23. McNulty MS, Dale JL, Lukert PD, Mankertz A, Randles JW, Todd D: Circoviridae. In:Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses, ed. van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, Wickner RB, pp 299-309, Academic Press, San Diego, CA 2000
  24. Meehan BM, McNeilly F, Todd D, Kennedy S, Jewhurst VA, Ellis JA, Hassard LE, Clark EG, Haines DM, Allan GM: Characterization of novel circovirus DNAs associated with wasting syndromes in pigs. J Gen Virol 79:2171-2179, 1998[Abstract]
  25. Mengeling WL, Ridpath JF, Vorwald AC: Size and antigenic comparisons among the structural proteins of selected autonomous parvoviruses. J Gen Virol 68:835-837, 1988
  26. Mengeling WL, Vorwald AC, Lager KM, Brockmeier SL: Diagnosis of porcine reproductive and respiratory syndrome using infected alveolar macrophages collected from live pigs. Vet Microbiol 49:105-115, 1996[CrossRef][ISI][Medline]
  27. Muirhead M: Sources of information on PMWS/PDNS. Vet Rec 150:456, 2002[ISI][Medline]
  28. Nawagitgul P, Harms PA, Morozov I, Thacker BJ, Sorden SD, Lekcharoensuk C, Paul PS: Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV. Clin Diagn Lab Immunol 9:33-40, 2002[Abstract/Free Full Text]
  29. Pogranichnyy RM, Yoon KJ, Harms PA, Swenson SL, Zimmerman JJ, Sorden SD: Characterization of immune response of young pigs to porcine circovirus type 2 infection. Viral Immunol 13:143-153, 2000[ISI][Medline]
  30. Rovira A, Balasch M, Segalés J, García L, Plana-Durán J, Rosell C, Ellerbrok H, Mankertz A, Domingo M: Experimental inoculation of conventional pigs with porcine reproductive and respiratory syndrome virus and porcine circovirus 2. J Virol 76:3232-3239, 2002[Abstract/Free Full Text]
  31. Sorden SD: Update on porcine circovirus and postweaning multisystemic wasting syndrome (PMWS). J Swine Health Prod 8:133-136, 2000
  32. Sorden SD, Harms PA, Nawagitgul P, Cavanaugh D, Paul PS: Development of a polyclonal-antibody-based immunohistochemical method for the detection of type 2 porcine circovirus in formalin-fixed, paraffin-embedded tissue. J Vet Diagn Invest 11:528-530, 1999[Abstract/Free Full Text]
  33. Tischer I, Gelderblom H, Vettermann W, Koch MA: A very small porcine virus with circular single-stranded DNA. Nature 295:64-66, 1982[CrossRef][Medline]
  34. Tischer I, Mields W, Wolff D, Vagt M, Griem W: Studies on epidemiology and pathogenicity of porcine circovirus. Arch Virol 91:271-276, 1986[CrossRef][ISI][Medline]
  35. Tischer I, Rasch R, Tochtermann G: Characterization of papovavirus- and picornavirus-like particles in permanent pig kidney cell lines. Zbl Bakt Hyg I Abt Orig A 226:153-167, 1974
  36. Walker IW, Konoby CA, Jewhurst VA, McNair I, McNeilly F, Meehan BM, Cottrell TS, Ellis JA, Allan GM: Development and application of a competitive enzyme-linked immunosorbent assay for the detection of serum antibodies to porcine circovirus type 2. J Vet Diagn Invest 12:400-405, 2000[Abstract/Free Full Text]
Request reprints from Dr. P. G. Halbur, Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011 (USA). E-mail: pghalbur{at}iastate.edu.




This article has been cited by other articles:


Home page
CVIHome page
T. Opriessnig, A. R. Patterson, J. Elsener, X. J. Meng, and P. G. Halbur
Influence of Maternal Antibodies on Efficacy of Porcine Circovirus Type 2 (PCV2) Vaccination To Protect Pigs from Experimental Infection with PCV2
Clin. Vaccine Immunol., March 1, 2008; 15(3): 397 - 401.
[Abstract] [Full Text] [PDF]


Home page
jvdiHome page
T. Opriessnig, X.-J. Meng, and P. G. Halbur
Porcine Circovirus Type 2 associated disease: Update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies
J Vet Diagn Invest, November 1, 2007; 19(6): 591 - 615.
[Abstract] [Full Text] [PDF]


Home page
jvdiHome page
K. Kawashima, K. Katsuda, and H. Tsunemitsu
Epidemiological investigation of the prevalence and features of postweaning multisystemic wasting syndrome in Japan
J Vet Diagn Invest, January 1, 2007; 19(1): 60 - 68.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
T. Opriessnig, N. E. McKeown, E.-M. Zhou, X.-J. Meng, and P. G. Halbur
Genetic and experimental comparison of porcine circovirus type 2 (PCV2) isolates from cases with and without PCV2-associated lesions provides evidence for differences in virulence.
J. Gen. Virol., October 1, 2006; 87(Pt 10): 2923 - 2932.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
T. Opriessnig, N. E. McKeown, K. L. Harmon, X. J. Meng, and P. G. Halbur
Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine.
Clin. Vaccine Immunol., August 1, 2006; 13(8): 923 - 929.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
T. Opriessnig, M. Fenaux, P. Thomas, M. J. Hoogland, M. F. Rothschild, X. J. Meng, and P. G. Halbur
Evidence of Breed-dependent Differences in Susceptibility to Porcine Circovirus Type-2-associated Disease and Lesions
Vet. Pathol., May 1, 2006; 43(3): 281 - 293.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
T. Opriessnig, E. L. Thacker, S. Yu, M. Fenaux, X.-J. Meng, and P. G. Halbur
Experimental Reproduction of Postweaning Multisystemic Wasting Syndrome in Pigs by Dual Infection with Mycoplasma hyopneumoniae and Porcine Circovirus Type 2
Vet. Pathol., November 1, 2004; 41(6): 624 - 640.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Fenaux, T. Opriessnig, P. G. Halbur, F. Elvinger, and X. J. Meng
A Chimeric Porcine Circovirus (PCV) with the Immunogenic Capsid Gene of the Pathogenic PCV Type 2 (PCV2) Cloned into the Genomic Backbone of the Nonpathogenic PCV1 Induces Protective Immunity against PCV2 Infection in Pigs
J. Virol., June 15, 2004; 78(12): 6297 - 6303.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Opriessnig, T.
Right arrow Articles by Halbur, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Opriessnig, T.
Right arrow Articles by Halbur, P. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS